Loading
A phase 1 trial of SGR-2921 run by Schrödinger, Inc., terminated.
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT05961839 by Schrödinger, Inc., with 66 participants enrolled, started 2023-09-27. Conditions recorded: Acute Myeloid Leukemia and High-Risk and Very High-Risk Myelodysplastic Syndromes. Interventions recorded: SGR-2921.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Schrödinger and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Schrödinger and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/